These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19635228)

  • 1. Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules.
    Bushnell D
    J Natl Compr Canc Netw; 2009 Jul; 7(7):760-4. PubMed ID: 19635228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Carcinoid tumors].
    Pregun I; Bodoky G; Rácz K; Tulassay Z
    Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Uprety D; Halfdanarson TR; Molina JR; Leventakos K
    Curr Treat Options Oncol; 2020 Aug; 21(11):86. PubMed ID: 32862320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
    Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
    World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
    Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
    J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide scanning for carcinoid tumours.
    Critchley M
    Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
    Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
    J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
    Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
    Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.
    Kvols LK
    Am J Med; 1986 Dec; 81(6B):49-55. PubMed ID: 2432781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Jul; 40(7):564-6. PubMed ID: 25546192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
    Khan MU; Morse M; Coleman RE
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):441-54. PubMed ID: 19088697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.